Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical Products Administration (NMPA) for its pegfilgrastim (Y shape) product. This Category 1 biologic is designed for use in patients with non-myeloid malignant tumors to reduce the incidence of infection with febrile neutropenia during treatment with bone marrow suppression anticancer drugs that are prone to causing such complications.
Pegfilgrastim (Y Shape): A Long-Acting Human Granulocyte Stimulating Factor
Pegfilgrastim (Y shape) is an in-house developed, long-acting human granulocyte stimulating factor. It stimulates the differentiation of bone marrow hematopoietic stem cells into granulocytes, promotes their proliferation, maturation, and release, and restores the number of neutrophils in peripheral blood. This helps reduce the incidence of infection in tumor patients following chemotherapy.
Amoytop Biotech’s Licensing Deal with Shanghai Fosun Pharmaceutical
In June 2023, Amoytop Biotech entered into a licensing agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196). This deal grants Fosun Pharmaceutical exclusive promotion and marketing rights to pegfilgrastim (Y shape) in mainland China. The partnership is expected to enhance the product’s reach and impact within the Chinese market.-Fineline Info & Tech
